Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia"

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Children's Oncology Group
Updated on 19 February 2024
absolute neutrophil count
renal function
gilbert's syndrome
growth factor
heart failure
ejection fraction
stem cell transplantation
myeloid leukemia
lymphoid leukemia
graft versus host disease
chronic myeloid leukemia
hydroxyurea
karnofsky performance status
tyrosine kinase inhibitor
major surgery
bosutinib
tyrosine
leukemia
immunodeficiency
platelet transfusion
schwartz
philadelphia chromosome
anagrelide
molecular diagnosis
chronic phase chronic myeloid leukemia
platelet transfusions
biologic agent
immunodeficiencies
t315i mutation
pediatric
differentiation therapy
hair thinning
cml - philadelphia chromosome
chromosome banding
blastic phase chronic myeloid leukemia

Summary

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML), to preliminary estimate the safety and tolerability and efficacy, and to evaluate the PK of bosutinib in this patient population.

Description

The Phase 1 part of the study employs a 6+4 design (no DLT in 6 patients or 1 DLT in 10 patients) and incorporates additional PK information before escalating to the next dose level. If there is unacceptable toxicity or if PK results have exceeded the acceptable exposure levels for the adult equivalent dose, further dose escalation will be prohibited. The Recommended Phase 2 Dose (RP2D) is defined as the dose that results in equivalent(approximately 20% of the adult values) PK exposure to 500 mg/day in adults and with 0 of 6 or <2 DLTs observed out of 10 evaluable patients with Ph+ CML and resistance or intolerance to prior TKI therapy. The 95% CI for DLT-risk with The phase 2 part of the study will enroll the following patient populations.

  • Newly diagnosed (ND): newly diagnosed Ph + CML patients in chronic phase (CP) Bosutinib in pediatric CML: ITCC-054/AAML1921
  • Resistant/intolerant (R/I): chronic phase or advanced (accelerated (AP) or blast phase (BP) Ph+ CML patients with resistance or intolerance to at least 1 prior TKI.

Details
Condition Blast Crisis, chronic phase chronic myelogenous leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive CML
Age 1years - 18years
Treatment Bosutinib
Clinical Study IdentifierNCT04258943
SponsorChildren's Oncology Group
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Inclusion criteria Phase 1 (R/I patients only)
Cytogenetic and molecular diagnosis of Philadelphia chromosome-positive CML[2] at either time of initial CML diagnosis or at time of study screening
Cytogenetics must be performed by chromosome banding analysis (CBA) of bone
marrow cell metaphases, and requires at least 20 metaphases
Only if dividing marrow cells cannot be obtained, or if there is an
insufficient number of metaphases, CBA can be substituted by interphase
fluorescence in situ hybridization (IFISH) of bone marrow or peripheral blood
cells, using dual color dual fusion probes, that allow the detection of BCR-
ABL+ nuclei; at least 200 nuclei should be counted
Qualitative RT-PCR should be performed on RNA extracted from freshly collected
bone marrow or peripheral blood cells. It identifies the transcript type
either e14a2 or 13a2 (also known as b3a2 and b2a2), or much more rarely e19a2
or e1a2, indicating the BCRABL protein weight (P210, rarely P230 or P190)
\. Resistance (suboptimal response or failure, as defined by 2013 European
Leukemia Net guidelines[3]) or intolerance (with or without suboptimal
response or failure) to at least one prior tyrosine kinase inhibitor (TKI) The
European LeukemiaNet guidelines[3] will be used to define suboptimal
response and failure to prior TKI therapy. Details are provided in appendices
(intolerance or failure after one TKI) and 4 (Failure after more than one
TKIs)
Intolerance to prior TKI therapy will be determined by the treating
investigator, but generally applies to patients who are unable to receive
standard or reduced doses of a TKI due to significant drug-related toxicity
and/or when the drug-related toxicity is not responding to appropriate medical
management. Patients who enroll as a result of intolerance to prior TKI
therapy may have any level of response to their prior therapy and still be
eligible
\. Age 1 and <18 years at day of attaining the informed consent
\. Lansky performance status 50% for patients 16 years of age, or Karnofsky
scale 50% for patients >16 years of age (appendix 5)
\. Adequate bone marrow function
For second-line and third-line CP CML patients
Absolute neutrophil count >1000/mm3 (>1.0 x109/L); Platelets 75,000/mm3 (75
x109/L) without any platelet transfusions during the preceding 7 days
For fourth-line CP and all for all AP/BP CML patients
Absolute neutrophil count >500/mm3 (>0.5 x109/L); Platelets 50,000/mm3 (50
x109/L) without any platelet transfusions during the preceding 7 days
\. Adequate Renal Function: Subjects must have a calculated creatinine
clearance (CrCl) 60mL/min/1.73 m2, using the Schwartz formula to estimate GFR
(see appendix 11)
\. Adequate liver function, including
AST/ALT 2.5 x upper limit normal (ULN) or 5 x ULN if attributable to disease
involvement of the liver; Total bilirubin 1.5 x ULN unless the patient has
documented Gilbert syndrome
\. Recovered to Grade 0-1, or to baseline, from any acute toxicities of prior
chemotherapy, immunotherapy, radiotherapy, differentiation therapy, or
biologic therapy, with the exception of alopecia
\. Able to reliably swallow whole capsules, whole tablets; or drug added to a
suitable foodstuff (from capsule contents, added to either apple sauce or
yoghurt); or tablets and/or capsules dissolved in water as an oral syringe
drinking solution, or tablets dissolved and administered by NG tube when
needed
\. Serum/urine pregnancy test (for all girls age of menarche) negative at
screening
\. Male and female patients of childbearing potential and at risk for
pregnancy must agree to use a highly effective method of contraception
throughout the study and for at least 30 days after the last dose of assigned
treatment. A patient is of childbearing potential if, in the opinion of the
Investigator, he/she is biologically capable of having children and is
sexually active
\. Written informed consent of parent(s)/legal guardian(s) and/or patients
(when applicable depending on age and local law and regulations)
\. Patients (including legally acceptable representative for minors where
applicable) who are willing and able to comply with scheduled visits
treatment plan, laboratory tests, and other study procedures
Exclusion criteria Phase 1 (R/I patients only)
Patients presenting with any of the following will not be included in the
study
Diagnosis of primary Ph+ acute lymphoblastic leukemia
In patients with AP/BP CML: leptomeningeal leukemia, defined as positive cytology on lumbar puncture (including both CNS2 and CNS3 status), or clinical symptoms or signs present. This assessment is not required for inclusion of CP CML patients
Extramedullary disease only
Documented prior history of T315I or V299L BCR-ABL1 mutations (Note: BCR-ABL1 mutation testing will be performed at screening for a baseline assessment, but results are not used to determine eligibility. This exclusion criterion is based on whether there is a known history of these mutations at the time of study entry. If these mutations become evident during the study the patient will go off study)
Any prior treatment with a TKI within 7 days prior to starting bosutinib treatment, or other antitumor or anti-leukemia treatment (with the exception of hydroxyurea and/or anagrelide) within 14 days prior to start of bosutinib treatment
Prior growth factors or biologic agents within 7 days prior to bosutinib treatment
Use of strong or moderate CYP3A4 inhibitors and inducers (see Appendix 8) within 7 days prior and/or concomitant to bosutinib treatment
Use of proton pump inhibitors (Ph-modifying agents) within 7 days prior and/or concomitant to bosutinib treatment
Prior radiotherapy within 3 months prior to bosutinib treatment
Allogeneic stem cell transplantation within 3 months prior to bosutinib treatment
Donor lymphocyte infusion (DLI) within 1 month prior to bosutinib treatment
Hereditary bone marrow failure disorder
Graft-versus-host disease (GVHD) within 60 days prior to bosutinib treatment
Major surgery within 14 days prior to bosutinib treatment (recovery from any previous surgery should be complete before day 1)
History of clinically significant or uncontrolled cardiac disease, including
History of or active congestive heart failure; Clinically significant
ventricular arrhythmia (such as ventricular tachycardia, ventricular
fibrillation, or Torsades de pointes); Diagnosed or suspected congenital or
acquired prolonged QT syndrome; History of prolonged QTc
\. Prolonged QTc (>450 msec, average of triplicate ECGs)
\. Need for medications known to prolong the QT interval
\. Pregnant and/or nursing women
\. Uncorrected hypomagnesemia or hypokalemia due to potential effects on the
QT interval
\. Left ventricular ejection fraction <50% or shortening fraction <28%
\. Recent or ongoing clinically significant gastrointestinal disorder that
may interfere with the intake or absorption of the drug
\. Evidence of serious active or uncontrolled bacterial, fungal or viral
infection
\. Known history of hepatitis B (HBV), hepatitis C (HCV), or human
immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
(AIDS)-related illness
\. Other severe acute or chronic medical or psychiatric condition or
laboratory abnormality that may increase the risk associated with study
participation or investigational product administration or may interfere with
the interpretation of study results and, in the judgment of the Investigator
would make the patient inappropriate for entry into this study
Inclusion criteria Phase 2
Resistant/Intolerant CML patients: R/I The inclusion criteria for the R/I patients in Phase 2 are identical to the Phase 1 inclusion criteria
Newly Diagnosed CML patients
Cytogenetic and molecular diagnosis of Philadelphia chromosome-positive CML at either time of initial CML diagnosis or at time of study screening
Cytogenetics must be performed by chromosome banding analysis (CBA) of bone
marrow cell metaphases, and requires at least 20 metaphases
Only if dividing marrow cells cannot be obtained, or if there is an
insufficient number of metaphases, CBA can be substituted by interphase
fluorescence in situ hybridization (IFISH) of bone marrow or peripheral blood
cells, using dual color dual fusion probes, that allow the detection of BCR-
ABL+ nuclei; at least 200 nuclei should be counted
Qualitative RT-PCR should be performed on RNA extracted from freshly collected
bone marrow or peripheral blood cells. It identifies the transcript type
either e14a2 or e13a2 (also known as b3a2 and b2a2), or much more rarely
e19a2, or e1a2, indicating the BCRABL protein weight (P210, rarely P230 or
P190)
\. Newly diagnosed CP Ph+ CML of 6 months (from initial diagnosis) without
any previous TKI treatment (with the exception of hydroxyurea and/or
anagrelide) for CML. Diagnosis of CP CML will be defined as per Appendix 1
\. Age 1 and <18 years at day of attaining the informed consent
\. Lansky performance status 50% for patients 16 years of age, or Karnofsky
scale 50% for patients >16 years of age (appendix 5)
\. Adequate Renal Function: Subjects must have a calculated creatinine
clearance (CrCl) 60 mL/min/1.73 m2, using the Schwartz formula to estimate GFR
(see appendix 11)
\. Adequate liver function, including
AST/ALT 2.5 x upper limit normal (ULN) or 5 x ULN if attributable to disease
involvement of the liver; Total bilirubin 1.5 x ULN unless the patient has
documented Gilbert syndrome
\. Able to reliably swallow whole capsules, whole tablets; or drug added to a
suitable foodstuff (from capsule contents, added to either apple sauce or
yogurt); or tablets and/or capsules dissolved as an oral syringe drinking
solution, or tablets dissolved and administered by NG tube when needed
\. Serum/urine pregnancy test (for all girls age of menarche) negative at
screening
\. Male and female patients of childbearing potential and at risk for
pregnancy must agree to use a highly effective method of contraception
throughout the study and for at least 30 days after the last dose of assigned
treatment. A patient is of childbearing potential if, in the opinion of the
Investigator, he/she is biologically capable of having children and is
sexually active
\. Written informed consent of parent(s)/legal guardian(s) and/or patients
(when applicable depending on age and local law and regulations)
\. Patients (including legally acceptable representative for minors where
applicable) who are willing and able to comply with scheduled visits
treatment plan, laboratory tests, and other study procedures
Exclusion criteria Phase 2
Resistant/Intolerant CML patients: R/I The exclusion criteria for the R/I cohort in Phase 2 are identical to the Phase 1 exclusion criteria
Newly Diagnosed CML patients
Patients presenting with any of the following will not be included in the
study
Diagnosis of primary Ph+ acute lymphoblastic leukemia
Extramedullary disease only
Documented prior history of T315I or V299L BCR-ABL1 mutations (Note: BCR-ABL1 mutation testing will be performed at screening for a baseline assessment, but results are not used to determine eligibility. This exclusion criterion is based on whether there is a known history of these mutations at the time of study entry. If these mutations become evident during the study the patient will go off study)
Any prior treatment with a TKI or other anti-tumor or anti-leukemia treatment (with the exception of hydroxyurea and/or anagrelide)
Prior growth factors or biologic agents within 7 days prior to bosutinib treatment
Use of strong or moderate CYP3A4 inhibitors and inducers (see Appendix 8) within 7 days prior and/or concomitant to bosutinib treatment
Use of proton pump inhibitors (Ph-modifying agents) within 7 days prior and/or concomitant to bosutinib treatment)
Hereditary bone marrow failure disorder
Major surgery within 14 days prior to bosutinib treatment (recovery from any previous surgery should be complete before day 1)
History of clinically significant or uncontrolled cardiac disease, including
History of or active congestive heart failure
Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
Diagnosed or suspected congenital or acquired prolonged QT syndrome
History of prolonged QTc
Prolonged QTc (>450 msec, average of triplicate ECGs)
Need for medications known to prolong the QT interval
Pregnant and/or nursing women
Uncorrected hypomagnesemia or hypokalemia due to potential effects on the QT interval
Left ventricular ejection fraction <50% or shortening fraction <28%
Recent or ongoing clinically significant gastrointestinal disorder that may interfere with the intake or absorption of the drug
Evidence of serious active or uncontrolled bacterial, fungal or viral infection
Known history of hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.